Search research articles
Contact Us
Filters
Showing results (11-20 of 49) with videos related to
Page
of 5
Sort By:
BMJ Open
|
June 17, 2019
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
Tadao Akizawa, Megumi Taguchi, Yoshimi Matsuda, et al.
Journal of the American Heart Association
|
April 7, 2023
Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study
Kazuomi Kario, Hiromi Rakugi, Daisuke Yarimizu, et al.
Journal of Atherosclerosis and Thrombosis
|
October 6, 2024
Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan
Emi Fujii, Junya Ako, Yuri Takahashi, et al.
Journal of Cardiology
|
January 18, 2026
A greater reduction in γ-GTP was associated with achieving BP <140/90 mmHg without antihypertensive medication among individuals who newly developed Grade I hypertension
Ryoichi Ohara, Fumiko Nakatsu, Kazuma Iekushi, et al.
Journal of Atherosclerosis and Thrombosis
|
March 17, 2023
Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan
Hironobu Mitani, Kota Suzuki, Junya Ako, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
January 13, 2026
Impact of treatment strategies incorporating sacubitril/valsartan on achievement of guideline-recommended blood pressure targets and representative safety outcomes
Tomohiro Katsuya, Fumiko Nakatsu, Shunsuke Eguchi, et al.
Nephron
|
August 7, 2019
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease
Tadao Akizawa, Iain C Macdougall, Jeffrey S Berns, et al.
Circulation
|
April 28, 2010
Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment
Chang-Hwan Yoon, Masamichi Koyanagi, Kazuma Iekushi, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
September 1, 2012
Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation
Kazutaka Shimizu, Yoshiaki Taniyama, Fumihiro Sanada, et al.
American Journal of Nephrology
|
March 11, 2019
Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies
Tadao Akizawa, Iain C Macdougall, Jeffrey S Berns, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 49) with videos related to
Sort By:
Page
of 5
BMJ Open
|
June 17, 2019
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
Tadao Akizawa, Megumi Taguchi, Yoshimi Matsuda, et al.
Journal of the American Heart Association
|
April 7, 2023
Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study
Kazuomi Kario, Hiromi Rakugi, Daisuke Yarimizu, et al.
Journal of Atherosclerosis and Thrombosis
|
October 6, 2024
Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan
Emi Fujii, Junya Ako, Yuri Takahashi, et al.
Journal of Cardiology
|
January 18, 2026
A greater reduction in γ-GTP was associated with achieving BP <140/90 mmHg without antihypertensive medication among individuals who newly developed Grade I hypertension
Ryoichi Ohara, Fumiko Nakatsu, Kazuma Iekushi, et al.
Journal of Atherosclerosis and Thrombosis
|
March 17, 2023
Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan
Hironobu Mitani, Kota Suzuki, Junya Ako, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
January 13, 2026
Impact of treatment strategies incorporating sacubitril/valsartan on achievement of guideline-recommended blood pressure targets and representative safety outcomes
Tomohiro Katsuya, Fumiko Nakatsu, Shunsuke Eguchi, et al.
Nephron
|
August 7, 2019
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease
Tadao Akizawa, Iain C Macdougall, Jeffrey S Berns, et al.
Circulation
|
April 28, 2010
Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment
Chang-Hwan Yoon, Masamichi Koyanagi, Kazuma Iekushi, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
September 1, 2012
Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation
Kazutaka Shimizu, Yoshiaki Taniyama, Fumihiro Sanada, et al.
American Journal of Nephrology
|
March 11, 2019
Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies
Tadao Akizawa, Iain C Macdougall, Jeffrey S Berns, et al.
Page
of 5